AtlantiCare
en Español
 
AboutHealth ServicesHealth ConditionsLocationsEvents & CoursesCommunityWays of Giving
  Search  
 
Health News
Today's Headlines
Health Alerts
Health News Feature
Future of Medicine
Health Observances
Product Recalls
Health Library
Illnesses & Conditions
Drug Guide
FDA Drug Approvals
Medical Tests
Self-Help Resources
Complementary Medicine
Medline Search
Health Topics
Allergies
Asthma
Back Pain
Cancer
Caregiver
Depression
Diabetes
GERD
Heart
Kidney
Men's Health
Orthopedic
Parenting
Patient Safety
Pregnancy
Senior
Stress
Stroke
Weight Mgmt
Women's Health
Healthy Living
Fitness
Nutrition
Mind & Body
Family & Home
Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

PET Scans May Help Detect Alzheimer's Brain Plaques


Injectable marker spots deposits, could be used to assess drugs in clinical trials

TUESDAY, Aug. 12 (HealthDay News) -- PET scans may provide doctors with a non-invasive method of detecting Alzheimer's disease-related brain plaques, Finnish researchers say.

Currently, the only reliable way to assess the presence of such plaques is through analysis of brain tissue samples obtained when a patient is alive or after death. In their study, University of Kuopio researchers examined 10 patients without severe dementia who'd undergone a biopsy of their brain's frontal cortex to check for normal-pressure hydrocephalus, an abnormal increase of cerebrospinal fluid in the brain.

Cognitive impairment is a symptom of both normal-pressure hydrocephalus and Alzheimer's, and 22 percent to 42 percent of patients with symptoms of normal-pressure hydrocephalus have brain lesions characteristic of Alzheimer's disease, according to background information in a news release about the study. The biopsies showed that six of the study participants had Alzheimer's-related beta-amyloid brain plaques.

For this study, all 10 patients were injected with a marker called carbon 11-labeled Pittsburgh Compound B ([11c]PiB) before having a 90-minute PET scan. The patients with beta-amyloid plaques had a higher uptake of the marker in certain brain areas than patients without the plaques.

"The study supports the use of [11C] PiB PET in the evaluation of beta-amyloid deposition in, for example, mild cognitive impairment, Alzheimer's disease or normal-pressure hydrocephalus," the researchers wrote.

"Large and prospective studies are required to verify whether [11C]PiB PET will become a tool in diagnosing Alzheimer's disease. Another potential use of [11c]PiB would be the quantitative monitoring of beta-amyloid deposits in the brain in subjects under treatment in pharmaceutical trials of early Alzheimer's disease targeting amyloid accumulation," they added.

The study was published online this week in the journal Archives of Neurology and was expected to be in the October print issue of the journal.

More information

The Fisher Center for Alzheimer's Research Foundation has more about Alzheimer's disease diagnosis.

SOURCE: JAMA/Archives journals, news release, Aug. 11, 2008
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay
 
 
Notice of Privacy Practices | | Disclaimer    © 2006 AtlantiCare AtlantiCare Access
 

  Powered by HEALTHvision